Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: A single centre case series
- PMID: 31778004
- PMCID: PMC6992514
- DOI: 10.1111/hae.13896
Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: A single centre case series
References
-
- Korth-Bradley JM, Rendo P, Smith L, et al. Altisent C Pharmacokinetics, efficacy, and safety of Nonacog Alfa in previously treated patients with moderately severe to severe hemophilia B. Clin Ther. 2016; 38(4):936–944. - PubMed
-
- Björkman S Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. Haemophilia. 2013; 19(5):753–757. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
